-- Scott Roberts
MONDAY, Nov. 15 (HealthDay News) -- Vyvanse (lisdexamfetamine
dimesylate) capsules have been approved by the U.S. Food and Drug
Administration to treat attention deficit hyperactivity disorder
(ADHD) among adolescents aged 13 to 17, maker Shire Pharmaceuticals
The FDA previously approved the drug for ADHD in adults and
children aged 6 years to 12 years, the British company said in a
Vyvanse was evaluated in clinical trials involving 314
adolescents with ADHD. The most frequently reported side effects
were decreased appetite, insomnia and weight loss. Results in
adolescents were consistent with earlier findings in adults and
children, Shire said.
Vyvanse is a controlled substance and should not be taken by
people with heart disease, hardening of the arteries,
moderate-to-severe high blood pressure, overactive thyroid,
glaucoma, a history of drug abuse, or with a known sensitivity to
stimulant medications, the company said.
To learn more about ADHD, visit the U.S.
Disease Control and Prevention.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.